Skip to main content

Advertisement

Log in

Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: medical therapy

Clinical and Experimental Nephrology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Schlesinger ER, Sultz HA, Mosher WE, Feldman JG. The nephrotic syndrome. Its incidence and implications for the community. Am J Dis Child. 1968;116:623–32.

    CAS  PubMed  Google Scholar 

  2. Koskimies O, Vilska J, Rapola J, Hallman N. Long-term outcome of primary nephrotic syndrome. Arch Dis Child. 1982;57:544–8.

    PubMed Central  CAS  PubMed  Google Scholar 

  3. Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr. Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. J Am Soc Nephrol. 1997;8:769–76.

    CAS  PubMed  Google Scholar 

  4. Arbeitsgemeinschaft für Pädiatrische Nephrologie. Effect of cytotoxic drugs in frequently relapsing nephrotic syndrome with and without steroid dependence. N Engl J Med. 1982;306:451–4

    Google Scholar 

  5. Fukui T, Yoshida M, Yamaguchi N. Minds Handbook for Guideline Development 2007. Tokyo: IGAKU-SHOIN Ltd.; 2007 (article in Japanese).

  6. Lohr KN. Clinical practice guidelines: directions for a new program. Washington, DC: National Academy Press. Field MJ; 1990.

    Google Scholar 

  7. The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children. J Pediatr. 1981;98:561–4.

    Google Scholar 

  8. International Study of Kidney Disease in Children. Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int. 1978;13:159–65

    Google Scholar 

  9. Gulati S, Sharma AP, Sharma RK, Gupta A, Gupta RK. Do current recommendations for kidney biopsy in nephrotic syndrome need modifications? Pediatr Nephrol. 2002;17:404–8.

    PubMed  Google Scholar 

  10. Cattran DC, Rao P. Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. Am J Kidney Dis. 1998;32:72–9.

    CAS  PubMed  Google Scholar 

  11. Kim JH, Park SJ, Yoon SJ, Lim BJ, Jeong HJ, Lee JS, Kim PK, Shin JI. Predictive factors for ciclosporin-associated nephrotoxicity in children with minimal change nephrotic syndrome. J Clin Pathol. 2011;64:516–9.

    CAS  PubMed  Google Scholar 

  12. Kengne-Wafo S, Massella L, Diomedi-Camassei F, Gianviti A, Vivarelli M, Greco M, Stringini GR, Emma F. Risk factors for cyclosporin A nephrotoxicity in children with steroid-dependant nephrotic syndrome. Clin J Am Soc Nephrol. 2009;4:1409–16.

    CAS  PubMed  Google Scholar 

  13. Iijima K, Hamahira K, Tanaka R, Kobayashi A, Nozu K, Nakamura H, Yoshikawa N. Risk factors for cyclosporine-induced tubulointerstitial lesions in children with minimal change nephrotic syndrome. Kidney Int. 2002;61:1801–5.

    PubMed  Google Scholar 

  14. Fujinaga S, Kaneko K, Muto T, Ohtomo Y, Murakami H, Yamashiro Y. Independent risk factors for chronic cyclosporine induced nephropathy in children with nephrotic syndrome. Arch Dis Child. 2006;91:666–70.

    PubMed Central  CAS  PubMed  Google Scholar 

  15. Ishikura K, Ikeda M, Hattori S, Yoshikawa N, Sasaki S, Iijima K, Nakanishi K, Yata N, Honda M. Effective and safe treatment with cyclosporine in nephrotic children: a prospective, randomized multicenter trial. Kidney Int. 2008;73:1167–73.

    CAS  PubMed  Google Scholar 

  16. Ishikura K, Yoshikawa N, Hattori S, Sasaki S, Iijima K, Nakanishi K, Matsuyama T, Yata N, Ando T, Honda M, for Japanese Study Group of Renal Disease in Children. Treatment with microemulsified cyclosporine in children with frequently relapsing nephrotic syndrome. Nephrol Dial Transplant. 2010;25:3956–62.

  17. Morgan C, Sis B, Pinsk M, Yiu V. Renal interstitial fibrosis in children treated with FK506 for nephrotic syndrome. Nephrol Dial Transplant. 2011;26:2860–5.

    CAS  PubMed  Google Scholar 

  18. Alternate-day versus intermittent prednisone in frequently relapsing nephrotic syndrome. A report of “Arbeitsgemeinschaft für Pädiatrische Nephrologie”. Lancet. 1979;1:401–3.

  19. Ueda N, Chihara M, Kawaguchi S, Niinomi Y, Nonoda T, Matsumoto J, Ohnishi M, Yasaki T. Intermittent versus long-term tapering prednisolone for initial therapy in children with idiopathic nephrotic syndrome. J Pediatr. 1988;112:122–6.

    CAS  PubMed  Google Scholar 

  20. Ehrich JH, Brodehl J. Long versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft for Pediatrische Nephrologie. Eur J Pediatr. 1993;152:357–61.

    CAS  PubMed  Google Scholar 

  21. Ksiazek J, Wyszyńska T. Short versus long initial prednisone treatment in steroid-sensitive nephrotic syndrome in children. Acta Paediatr. 1995;84:889–93.

    CAS  PubMed  Google Scholar 

  22. Bagga A, Hari P, Srivastava RN. Prolonged versus standard prednisolone therapy for initial episode of nephrotic syndrome. Pediatr Nephrol. 1999;13:824–7.

    CAS  PubMed  Google Scholar 

  23. Hiraoka M, Tsukahara H, Matsubara K, Tsurusawa M, Takeda N, Haruki S, Hayashi S, Ohta K, Momoi T, Ohshima Y, Suganuma N, Mayumi M. West Japan Cooperative Study Group of Kidney Disease in Children. A randomized study of two long-course prednisolone regimens for nephrotic syndrome in children. Am J Kidney Dis. 2003;41:1155–62.

    CAS  PubMed  Google Scholar 

  24. Norero C, Delucchi A, Lagos E, Rosati P. Initial therapy of primary nephrotic syndrome in children: evaluation in a period of 18 months of two prednisone treatment schedules. Chilean Co-operative Group of Study of Nephrotic Syndrome in Children. Rev Med Chil. 1996;124:567–72 (article in Spanish).

    CAS  PubMed  Google Scholar 

  25. Yoshikawa N, Ito H, Takekoshi Y, Honda M, Awazu M, Iijima K, Nakamura H, Seino Y, Takeda N, Hattori S, Matsuda I. Standard versus long-term prednisolone with Sairei-to for initial therapy in childhood steroid-responsive nephrotic syndrome: a prospective controlled study. Jpn J Nephrol. 1998;40:587–90 (article in Japanese).

    CAS  Google Scholar 

  26. Lande MB, Gullion C, Hogg RJ, Gauthier B, Shah B, Leonard MB, Bonilla-Felix M, Nash M, Roy S 3rd, Strife CF, Arbus G. Long versus standard initial steroid therapy for children with the nephrotic syndromeA report from the Southwest Pediatric Nephrology Study Group. Pediatr Nephrol. 2003;18:342–6.

    PubMed  Google Scholar 

  27. Hirano D, Nishizaki N, Kanai H, Hara S, Ohtomo Y, Umino D, Fujinaga S. Long-term outcome of children treated with the ISKDC regimen for the first episode of INS. Jpn J Nephrol. 2010;52:1029–36 (article in Japanese).

    Google Scholar 

  28. Hodson EM, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev. 2007;(4):CD001533.

  29. Ekka BK, Bagga A, Srivastava RN. Single- versus divided-dose prednisolone therapy for relapses of nephrotic syndrome. Pediatr Nephrol. 1997;11(5):597–9.

    CAS  PubMed  Google Scholar 

  30. Hoyer PF, Brodeh J. Initial treatment of idiopathic nephrotic syndrome in children: prednisone versus prednisone plus cyclosporine A: a prospective, randomized trial. J Am Soc Nephrol. 2006;17:1151–7.

    CAS  PubMed  Google Scholar 

  31. Hayashi M, Kimura N, Fukatsu A. Combined effect of cyclosporin and prednisolone for minimal change nephrotic syndrome: comparison with prednisolone therapy. Jpn J Nephrol. 2008;50:581–7 (article in Japanese).

    Google Scholar 

  32. Yoshikawa N, Ito H. Kampo medicine for pediatric renal disease: nephrotic syndrome. J Tradit Sino-Jpn Med. 1991;12:24–7 (article in Japanese).

    Google Scholar 

  33. Hodson EM, Willis NS, Craig JC. Non-corticosteroid treatment for nephrotic syndrome in children. Cochrane Database Syst Rev. 2008;(1):CD002290.

  34. Ponticelli C, Edefonti A, Ghio L, Rizzoni G, Rinaldi S, Gusmano R, Lama G, Zacchello G, Confalonieri R, Altieri P. Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial. Nephrol Dial Transplant. 1993;8:1326–32.

    CAS  PubMed  Google Scholar 

  35. Niaudet P, Broyer M, Habib R. Treatment of idiopathic nephrotic syndrome with cyclosporin A in children. Clin Nephrol. 1991;35 Suppl1:S31–6.

  36. El-Husseini A, El-Basuony F, Mahmoud I, Sheashaa H, Sabry A, Hassan R, Taha N, Hassan N, Sayed-Ahmad N, Sobh M. Long-term effects of cyclosporine in children with idiopathic nephrotic syndrome: a single-centre experience. Nephrol Dial Transplant. 2005;20:2433–8.

    CAS  PubMed  Google Scholar 

  37. Kitano Y, Yoshikawa N, Tanaka R, Nakamura H, Ninomiya M, Ito H. Ciclosporin treatment in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 1990;4(5):474–7.

    CAS  PubMed  Google Scholar 

  38. Tanaka R, Yoshikawa N, Kitano Y, Ito H, Nakamura H. Long-term ciclosporin treatment in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 1993;7:249–52.

    CAS  PubMed  Google Scholar 

  39. Inoue Y, Iijima K, Nakamura H, Yoshikawa N. Two-year cyclosporin treatment in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 1999;13(1):33–8.

    CAS  PubMed  Google Scholar 

  40. Ishikura K, Yoshikawa N, Nakazato H, Sasaki S, Iijima K, Nakanishi K, Matsuyama T, Ito S, Yata N, Ando T, Honda M. Japanese Study Group of Renal Disease in Children. Two-year follow-up of a prospective clinical trial of cyclosporine for frequently relapsing nephrotic syndrome in children. Clin J Am Soc Nephrol. 2012;7:1576–83.

    PubMed Central  CAS  PubMed  Google Scholar 

  41. Kemper MJ, Kuwertz-Broeking E, Bulla M, Mueller-Wiefel DE, Neuhaus TJ. Recurrence of severe steroid dependency in cyclosporin A-treated childhood idiopathic nephrotic syndrome. Nephrol Dial Transplant. 2004;19:1136–41.

    CAS  PubMed  Google Scholar 

  42. Niaudet P, Reigneau O, Humbert H. A pharmacokinetic study of Neoral in childhood steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2001;16:154–5.

    CAS  PubMed  Google Scholar 

  43. David-Neto E, Araujo LM, Brito ZM, Alves CF, Lemos FC, Yagyu EM, Nahas WC, Ianhez LE. Sampling strategy to calculate the cyclosporin-A area under the time-concentration curve. Am J Transplant. 2002;2:546–50.

    CAS  PubMed  Google Scholar 

  44. Filler G. How should microemulsified cyclosporine A (Neoral) therapy in patients with nephrotic syndrome be monitored. Nephrol Dial Transplant. 2005;20:1032–4.

    CAS  PubMed  Google Scholar 

  45. Suzuki K, Oki E, Tsuruga K, Aizawa-Yashiro T, Ito E, Tanaka H. Benefits of once-daily administration of cyclosporine a for children with steroid-dependent, relapsing nephrotic syndrome. Tohoku J Exp Med. 2010;220:183–6.

    CAS  PubMed  Google Scholar 

  46. Fujinaga S, Hirano D, Murakami H, Ohtomo Y, Shimizu T, Kaneko K. Nephrotoxicity of once-daily cyclosporine A in minimal change nephrotic syndrome. Pediatr Nephrol. 2012;27:671–4.

    PubMed  Google Scholar 

  47. Barratt TM, Soothill JF. Controlled trial of cyclophosphamide in steroid-sensitive relapsing nephrotic syndrome of childhood. Lancet. 1970;2:479–82.

    CAS  PubMed  Google Scholar 

  48. International Study of Kidney Disease in Children (ISKDC). Prospective, controlled trial of cyclophosphamide therapy in children with nephrotic syndrome. Report of the International study of Kidney Disease in Children. Lancet. 1974;2:423–7.

  49. Barratt TM, Cameron JS, Chantler C, Ogg CS, Soothill JF. Comparative trial of 2 weeks and 8 weeks cyclophosphamide in steroid-sensitive relapsing nephrotic syndrome of childhood. Arch Dis Child. 1973;48:286–90.

    PubMed Central  CAS  PubMed  Google Scholar 

  50. Cyclophosphamide treatment of steroid dependent nephrotic syndrome: comparison of eight week with 12 week course. Report of Arbeitsgemeinschaft für Pädiatrische Nephrologie. Arch Dis Child 1987;62:1102–6.

  51. Ueda N, Kuno K, Ito S. Eight and 12 week courses of cyclophosphamide in nephrotic syndrome. Arch Dis Child. 1990;65:1147–50.

    PubMed Central  CAS  PubMed  Google Scholar 

  52. Kyrieleis HA, Levtchenko EN, Wetzels JF. Long-term outcome after cyclophosphamide treatment in children with steroid-dependent and frequently relapsing minimal change nephrotic syndrome. Am J Kidney Dis. 2007;49:592–7.

    CAS  PubMed  Google Scholar 

  53. Cammas B, Harambat J, Bertholet-Thomas A, Bouissou F, Morin D, Guigonis V, Bendeddouche S, Afroukh-Hacini N, Cochat P, Llanas B, Decramer S, Ranchin B. Long-term effects of cyclophosphamide therapy in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. Nephrol Dial Transplant. 2011;26:178–84.

    CAS  PubMed  Google Scholar 

  54. Vester U, Kranz B, Zimmermann S, Hoyer PF. Cyclophosphamide in steroid-sensitive nephrotic syndrome: outcome and outlook. Pediatr Nephrol. 2003;18:661–4.

    PubMed  Google Scholar 

  55. Azib S, Macher MA, Kwon T, Dechartres A, Alberti C, Loirat C, Deschênes G, Baudouin V. Cyclophosphamide in steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2011;26:927–32.

    PubMed  Google Scholar 

  56. Srivastava RN, Agarwal RK, Choudhry VP, Moudgil A, Bhuyan UN, Sunderam KR. Cyclophosphamide therapy in frequently relapsing nephrotic syndrome with and without steroid dependence. Int J Pediatr Nephrol. 1985;6:245–50.

    CAS  PubMed  Google Scholar 

  57. Zagury A, de Oliveira AL, de Moraes CA, de Araujo Montalvão JA, Novaes RH, de Sá VM, Monteiro de Carvalho Dde B, Matuck T. Long-term follow-up after cyclophosphamide therapy in steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2011;26:915–20.

  58. Garin EH, Pryor ND, Fennell RS 3rd, Richard GA. Pattern of response to prednisone in idiopathic, minimal lesion nephrotic syndrome as a criterion in selecting patients for cyclophosphamide therapy. J Pediatr. 1978;92:304–8.

    CAS  PubMed  Google Scholar 

  59. Kemper MJ, Altrogge H, Ludwig K, Timmermann K, Müller-Wiefel DE. Unfavorable response to cyclophosphamide in steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2000;14:772–5.

    CAS  PubMed  Google Scholar 

  60. Latta K, von Schnakenburg C, Ehrich JH. A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children. Pediatr Nephrol. 2001;16:271–82.

    CAS  PubMed  Google Scholar 

  61. Siegel NJ, Gaudio KM, Krassner LS, McDonald BM, Anderson FP, Kashgarian M. Steroid-dependent nephrotic syndrome in children: histopathology and relapses after cyclophosphamide treatment. Kidney Int. 1981;19:454–9.

    CAS  PubMed  Google Scholar 

  62. Tejani A, Phadke K, Nicastri A, Adamson O, Chen CK, Trachtman H, Tejani C. Efficacy of cyclophosphamide in steroid-sensitive childhood nephrotic syndrome with different morphological lesions. Nephron. 1985;41:170–3.

    CAS  PubMed  Google Scholar 

  63. Gulati S, Pokhariyal S, Sharma RK, Elhence R, Kher V, Pandey CM, Gupta A. Pulse cyclophosphamide therapy in frequently relapsing nephrotic syndrome. Nephrol Dial Transplant. 2001;16:2013–7.

    CAS  PubMed  Google Scholar 

  64. Bircan Z, Kara B. Intravenous cyclophosphamide is the drug of choice for steroid dependent nephrotic syndrome. Pediatr Int. 2003;45:65–7.

    CAS  PubMed  Google Scholar 

  65. Prasad N, Gulati S, Sharma RK, Singh U, Ahmed M. Pulse cyclophosphamide therapy in steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2004;19:494–8.

    PubMed  Google Scholar 

  66. Donia AF, Gazareen SH, Ahmed HA, Moustafa FE, Shoeib AA, Ismail AM, Khamis S, Sobh MA. Pulse cyclophosphamide inadequately suppresses reoccurrence of minimal change nephrotic syndrome in corticoid-dependent children. Nephrol Dial Transplant. 2003;18:2054–8.

    CAS  PubMed  Google Scholar 

  67. Wetzels JF. Cyclophosphamide-induced gonadal toxicity: a treatment dilemma in patients with lupus nephritis. Neth J Med. 2004;62:347–52.

    CAS  PubMed  Google Scholar 

  68. Hodson EM, Craig JC, Willis NS. Evidence-based management of steroid-sensitive nephrotic syndrome. Pediatr Nephrol. 2005;20:1523–30.

    PubMed  Google Scholar 

  69. Rivkees SA, Crawford JD. The relationship of gonadal activity and chemotherapy-induced gonadal damage. JAMA. 1988;259:2123–5.

    CAS  PubMed  Google Scholar 

  70. Yoshioka K, Ohashi Y, Sakai T, Ito H, Yoshikawa N, Nakamura H, Tanizawa T, Wada H, Maki S. A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome. Kidney Int. 2000;58:317–24.

    CAS  PubMed  Google Scholar 

  71. Kawasaki Y, Hosoya M, Kobayashi S, Ohara S, Onishi N, Takahashi A, Isome M, Suzuki H. Oral mizoribine pulse therapy for patients with steroid-resistant and frequently relapsing steroid-dependent nephrotic syndrome. Nephrol Dial Transplant. 2005;20(10):2243–7.

    CAS  PubMed  Google Scholar 

  72. Kawasaki Y, Takano K, Isome M, Suzuki J, Suyama K, Kanno H, Fujiki T, Suzuki H, Hosoya M. Efficacy of single dose of oral mizoribine pulse therapy two times per week for frequently relapsing nephrotic syndrome. J Nephrol. 2007;20:52–6.

    CAS  PubMed  Google Scholar 

  73. Fujieda M, Ishihara M, Morita T, Hayashi A, Utsunomiya Y, Ohta T, Sakano T, Wakiguchi H. Effect of oral mizoribine pulse therapy for frequently relapsing steroid-dependent nephrotic syndrome. Clin Nephrol. 2008;69:179–84.

    CAS  PubMed  Google Scholar 

  74. Ohtomo Y, Fujinaga S, Takada M, Murakami H, Akashi S, Shimizu T, Kaneko K, Yamashiro Y. High-dose mizoribine therapy for childhood-onset frequently relapsing steroid-dependent nephrotic syndrome with cyclosporin nephrotoxicity. Pediatr Nephrol. 2005;20:1744–9.

    PubMed  Google Scholar 

  75. Fujinaga S, Hirano D, Nishizaki N, Someya T, Ohtomo Y, Ohtsuka Y, Shimizu T, Kaneko K. Single daily high-dose mizoribine therapy for children with steroid-dependent nephrotic syndrome prior to cyclosporine administration. Pediatr Nephrol. 2011;26:479–83.

    PubMed  Google Scholar 

  76. Goto M, Ikeda M, Hataya H, Ishikura K, Hamasaki Y, Honda M. Beneficial and adverse effects of high-dosage MZR therapy in the management of children with frequently relapsing nephrotic syndrome. Jpn J Nephrol. 2006;48:365–70 (article in Japanese).

    CAS  Google Scholar 

  77. Guigonis V, Dallocchio A, Baudouin V, Dehennault M, Hachon-Le Camus C, Afanetti M, Groothoff J, Llanas B, Niaudet P, Nivet H, Raynaud N, Taque S, Ronco P, Bouissou F. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol. 2008;23:1269–79.

  78. Kamei K, Ito S, Nozu K, Fujinaga S, Nakayama M, Sako M, Saito M, Yoneko M, Iijima K. Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol. 2009;24:1321–8.

    PubMed  Google Scholar 

  79. Prytuła A, Iijima K, Kamei K, Geary D, Gottlich E, Majeed A, Taylor M, Marks SD, Tuchman S, Camilla R, Ognjanovic M, Filler G, Smith G, Tullus K. Rituximab in refractory nephrotic syndrome. Pediatr Nephrol. 2010;25:461–8.

    PubMed  Google Scholar 

  80. Sellier-Leclerc AL, Macher MA, Loirat C, Guérin V, Watier H, Peuchmaur M, Baudouin V, Deschênes G. Rituximab efficiency in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2010;25:1109–15.

    PubMed  Google Scholar 

  81. Gulati A, Sinha A, Jordan SC, Hari P, Dinda AK, Sharma S, Srivastava RN, Moudgil A, Bagga A. Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report. Clin J Am Soc Nephrol. 2010;5:2207–12.

    PubMed Central  CAS  PubMed  Google Scholar 

  82. Fujinaga S, Hirano D, Nishizaki N, Kamei K, Ito S, Ohtomo Y, Shimizu T. Kaneko K.ingle infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine. Pediatr Nephrol. 2010;25:539–44.

    PubMed  Google Scholar 

  83. Sinha A, Bagga A, Gulati A, Hari P. Short-term efficacy of rituximab versus tacrolimus in steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2012;27:235–41.

    PubMed  Google Scholar 

  84. Ravani P, Magnasco A, Edefonti A, Murer L, Rossi R, Ghio L, Benetti E, Scozzola F, Pasini A, Dallera N, Sica F, Belingheri M, Scolari F, Ghiggeri GM. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol. 2011;6:1308–15.

    PubMed Central  CAS  PubMed  Google Scholar 

  85. Kemper MJ, Gellermann J, Habbig S, Krmar RT, Dittrich K, Jungraithmayr T, Pape L, Patzer L, Billing H, Weber L, Pohl M, Rosenthal K, Rosahl A, Mueller-Wiefel DE, Dötsch J. Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome. Nephrol Dial Transplant. 2012;27:1910–5.

    CAS  PubMed  Google Scholar 

  86. Sellier-Leclerc AL, Baudouin V, Kwon T, Macher MA, Guérin V, Lapillonne H, Deschênes G, Ulinski T. Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood–follow-up after CD19 recovery. Nephrol Dial Transplant. 2012;27:1083–9.

    CAS  PubMed  Google Scholar 

  87. Hiramoto R, Matsumoto S, Eguchi H, Miyoshi Y, Komori I, Akikusa B, Shibata S, Kamei K. Iijima K A case of a 7-year-old boy with steroid-dependent nephrotic syndrome who developed severe neutropenia three months after the administration of rituximab. Japanese Journal of Pediatric Nephrology. 2009;22:97–101 (article in Japanese).

    Google Scholar 

  88. Sato M, Ito S, Ogura M, Kamei K, Miyairi I, Miyata I, Higuchi M, Matsuoka K. Atypical Pneumocystis jiroveci pneumonia with multiple nodular granulomas after rituximab for refractory nephrotic syndrome. Pediatr Nephrol. 2013;28:145–9

    PubMed  Google Scholar 

  89. Gea-Banacloche JC. Rituximab-associated infections. Semin Hematol. 2010;47:187–98.

    CAS  PubMed  Google Scholar 

  90. Chaumais MC, Garnier A, Chalard F, Peuchmaur M, Dauger S, Jacqz-Agrain E, Deschênes G. Fatal pulmonary fibrosis after rituximab administration. Pediatr Nephrol. 2009;24:1753–5.

    PubMed  Google Scholar 

  91. Ardelean DS, Gonska T, Wires S, Cutz E, Griffiths A, Harvey E, Tse SM, Benseler SM. Severe ulcerative colitis after rituximab therapy. Pediatrics. 2010;126:e243–6.

    PubMed  Google Scholar 

  92. Bagga A, Hari P, Moudgil A, Jordan SC. Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome. Am J Kidney Dis. 2003;42:1114–20.

    CAS  PubMed  Google Scholar 

  93. Hogg RJ, Fitzgibbons L, Bruick J, Bunke M, Ault B, Baqi N, Trachtman H, Swinford R. Mycophenolate mofetil in children with frequently relapsing nephrotic syndrome: a report from the Southwest Pediatric Nephrology Study Group. Clin J Am Soc Nephrol. 2006;1:1173–8.

    CAS  PubMed  Google Scholar 

  94. Afzal K, Bagga A, Menon S, Hari P, Jordan SC. Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2007;22:2059–65.

    PubMed  Google Scholar 

  95. Barletta GM, Smoyer WE, Bunchman TE, Flynn JT, Kershaw DB. Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome. Pediatr Nephrol. 2003;18:833–7.

    PubMed  Google Scholar 

  96. Ulinski T, Dubourg L, Saïd MH, Parchoux B, Ranchin B, Cochat P. Switch from cyclosporine A to mycophenolate mofetil in nephrotic children. Pediatr Nephrol. 2005;20:482–5.

    PubMed  Google Scholar 

  97. Mendizábal S, Zamora I, Berbel O, Sanahuja MJ, Fuentes J, Simon J. Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome. Pediatr Nephrol. 2005;20:914–9.

    PubMed  Google Scholar 

  98. Okada M, Sugimoto K, Yagi K, Yanagida H, Tabata N, Takemura T. Mycophenolate mofetil therapy for children with intractable nephrotic syndrome. Pediatr Int. 2007;49:933–7.

    CAS  PubMed  Google Scholar 

  99. Fujinaga S, Ohtomo Y, Umino D, Takemoto M, Shimizu T, Yamashiro Y, Kaneko K. A prospective study on the use of mycophenolate mofetil in children with cyclosporine-dependent nephrotic syndrome. Pediatr Nephrol. 2007;22:71–6.

    PubMed  Google Scholar 

  100. Fujinaga S, Ohtomo Y, Hirano D, Nishizaki N, Someya T, Ohtsuka Y, Kaneko K, Shimizu T. Mycophenolate mofetil therapy for childhood-onset steroid dependent nephrotic syndrome after long-term cyclosporine: extended experience in a single center. Clin Nephrol. 2009;72:268–73.

    CAS  PubMed  Google Scholar 

  101. Gellermann J, Querfeld U. Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil. Pediatr Nephrol. 2004;19:101–4.

    PubMed  Google Scholar 

  102. Dorresteijn EM. Kist-van Holthe JE, Levtchenko EN, Nauta J, Hop WC, van der Heijden AJ. Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome. Pediatr Nephrol. 2008;23:2013–20.

    PubMed  Google Scholar 

  103. Novak I, Frank R, Vento S, Vergara M, Gauthier B, Trachtman H. Efficacy of mycophenolate mofetil in pediatric patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2005;20:1265–8.

    PubMed  Google Scholar 

  104. Al-Akash S, Al-Makdama A. Mycophenolate mofetil in children with steroid-dependent and/or frequently relapsing nephrotic syndrome. Ann Saudi Med. 2005;25:380–4.

    PubMed  Google Scholar 

  105. Baudouin V, Alberti C, Lapeyraque AL, Bensman A, André JL, Broux F, Cailliez M, Decramer S, Niaudet P, Deschênes G, Jacqz-Aigrain E, Loirat C. Mycophenolate mofetil for steroid-dependent nephrotic syndrome: a phase II Bayesian trial. Pediatr Nephrol. 2012;27:389–96.

    PubMed  Google Scholar 

  106. Dittrich K, Knerr I, Rascher W, Dötsch J. Transient insulin-dependent diabetes mellitus in children with steroid-dependent idiopathic nephrotic syndrome during tacrolimus treatment. Pediatr Nephrol. 2006;21:958–61.

    PubMed  Google Scholar 

  107. Sinha MD, MacLeod R, Rigby E, Clark AG. Treatment of severe steroid-dependent nephrotic syndrome (SDNS) in children with tacrolimus. Nephrol Dial Transplant. 2006;21:1848–54.

    CAS  PubMed  Google Scholar 

  108. Dötsch J, Dittrich K, Plank C, Rascher W. Is tacrolimus for childhood steroid-dependent nephrotic syndrome better than ciclosporin A. Nephrol Dial Transplant. 2006;21:1761–3.

    PubMed  Google Scholar 

  109. Ehrich JH, Geerlings C, Zivicnjak M, Franke D, Geerlings H, Gellermann J. Steroid-resistant idiopathic childhood nephrosis: overdiagnosed and undertreated. Nephrol Dial Transplant. 2007;22:2183–93.

    PubMed  Google Scholar 

  110. Mori K, Honda M, Ikeda M. Efficacy of methylprednisolone pulse therapy in steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2004;19:1232–6.

    PubMed  Google Scholar 

  111. Hamasaki Y, Yoshikawa N, Hattori S, Sasaki S, Iijima K, Nakanishi K, Matsuyama T, Ishikura K, Yata N, Kaneko T, Honda M. Japanese Study Group of Renal Disease. Cyclosporine and steroid therapy in children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2009;24:2177–85.

    PubMed  Google Scholar 

  112. Bagga A, Mudigoudar BD, Hari P, Vasudev V. Enalapril dosage in steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2004;19:45–50.

    PubMed  Google Scholar 

  113. Karle SM, Uetz B, Ronner V, Glaeser L, Hildebrandt F, Fuchshuber A. Novel mutations in NPHS2 detected in both familial and sporadic steroid-resistant nephrotic syndrome. J Am Soc Nephrol. 2002;13:388–93.

    CAS  PubMed  Google Scholar 

  114. Weber S, Gribouval O, Esquivel EL, Morinière V, Tête MJ, Legendre C, Niaudet P, Antignac C. NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence. Kidney Int. 2004;66:571–9.

    CAS  PubMed  Google Scholar 

  115. Chernin G, Heeringa SF, Gbadegesin R, Liu J, Hinkes BG, Vlangos CN, Vega-Warner V, Hildebrandt F. Low prevalence of NPHS2 mutations in African American children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2008;23:1455–60.

    PubMed  Google Scholar 

  116. Santín S, Bullich G, Tazón-Vega B, García-Maset R, Giménez I, Silva I, Ruíz P, Ballarín J, Torra R, Ars E. Clinical utility of genetic testing in children and adults with steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol. 2011;6:1139–48.

    PubMed Central  PubMed  Google Scholar 

  117. Ponticelli C, Rizzoni G, Edefonti A, Altieri P, Rivolta E, Rinaldi S, Ghio L, Lusvarghi E, Gusmano R, Locatelli F, Pasquali S, Castellani A, Della Casa Alberighi O. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int. 1993;43:1377–84.

    CAS  PubMed  Google Scholar 

  118. Lieberman KV, Tejani A. A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J Am Soc Nephrol. 1996;7:56–63.

    CAS  PubMed  Google Scholar 

  119. Choudhry S, Bagga A, Hari P, Sharma S, Kalaivani M, Dinda A. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial. Am J Kidney Dis. 2009;53:760–9.

    CAS  PubMed  Google Scholar 

  120. Mahmoud I, Basuni F, Sabry A, El-Husseini A, Hassan N, Ahmad NS, Elbaz M, Moustafa F, Sobh M. Single-centre experience with cyclosporin in 106 children with idiopathic focal segmental glomerulosclerosis. Nephrol Dial Transplant. 2005;20:735–42.

    PubMed  Google Scholar 

  121. Hamasaki Y, Yoshikawa N, Nakazato H, Sasaki S, Iijima K, Nakanishi K, Matsuyama T, Ishikura K, Ito S, Kaneko T, Honda M, for Japanese Study Group of Renal Disease in Children. Prospective 5-year follow-up of cyclosporine treatment in children with steroid-resistant nephrosis. Pediatr Nephrol. 2013;28:765–71.

  122. Ingulli E, Singh A, Baqi N, Ahmad H, Moazami S, Tejani A. Aggressive, long-term cyclosporine therapy for steroid-resistant focal segmental glomerulosclerosis. J Am Soc Nephrol. 1995;5:1820–5.

    CAS  PubMed  Google Scholar 

  123. Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, Maxwell DR, Kunis CL. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int. 1999;56:2220–6.

    CAS  PubMed  Google Scholar 

  124. Heering P, Braun N, Müllejans R, Ivens K, Zäuner I, Fünfstück R, Keller F, Krämer BK, Schollmeyer P, Risler T, Grabensee B. German Collaborative Glomerulonephritis Study Group Cyclosporine A and chlorambucil in the treatment of idiopathic focal segmental glomerulosclerosis. Am J Kidney Dis. 2004;43:10–8.

  125. Niaudet P. Treatment of childhood steroid-resistant idiopathic nephrosis with a combination of cyclosporine and prednisone. French Society of Pediatric Nephrology. J Pediatr. 1994;125:981–6.

    CAS  PubMed  Google Scholar 

  126. Sako M, Iijima K, Saito M, Ohashi Y, Yoshikawa N. Cyclosporine C2 monitaring for frequently relapsing nephrotic syndrome in children: a randomized controlled trial. Jpn J Nephrol. 2012;54:253 (article in Japanese).

    Google Scholar 

  127. Naito M, Takei T, Eguchi A, Uchida K, Tsuchiya K, Nitta K. Monitoring of blood cyclosporine concentration in steroid-resistant nephrotic syndrome. Intern Med. 2008;47:1567–72.

    PubMed  Google Scholar 

  128. Ishikura K, Ikeda M, Hamasaki Y, Hataya H, Nishimura G, Hiramoto R, Honda M. Nephrotic state as a risk factor for developing posterior reversible encephalopathy syndrome in paediatric patients with nephrotic syndrome. Nephrol Dial Transplant. 2008;23:2531–2536.

    PubMed  Google Scholar 

  129. Segarra A, Vila J, Pou L, Majó J, Arbós A, Quiles T, Piera LL. Combined therapy of tacrolimus and corticosteroids in cyclosporin-resistant or -dependent idiopathic focal glomerulosclerosis: a preliminary uncontrolled study with prospective follow-up. Nephrol Dial Transplant. 2002;17:655–62.

    CAS  PubMed  Google Scholar 

  130. Waldo FB, Benfield MR, Kohaut EC. Therapy of focal and segmental glomerulosclerosis with methylprednisolone, cyclosporine A, and prednisone. Pediatr Nephrol. 1998;12:397–400.

    CAS  PubMed  Google Scholar 

  131. Yorgin PD, Krasher J, Al-Uzri AY. Pulse methylprednisolone treatment of idiopathic steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2001;16:245–50.

    CAS  PubMed  Google Scholar 

  132. Shenoy M, Plant ND, Lewis MA, Bradbury MG, Lennon R, Webb NJ. Intravenous methylprednisolone in idiopathic childhood nephrotic syndrome. Pediatr Nephrol. 2010;25:899–903.

    PubMed  Google Scholar 

  133. Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr. Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis. A report of the International Study of Kidney Disease in Children. Pediatr Nephrol. 1996;10:590–3.

    CAS  PubMed  Google Scholar 

  134. Plank C, Kalb V, Hinkes B, Hildebrandt F, Gefeller O, Rascher W. Arbeits-gemeinschaft für Pädiatrische Nephrologie. Cyclosporin A is superior to cyclophosphamide in children with steroid-resistant nephrotic syndrome-a randomized controlled multicentre trial by the Arbeitsgemeinschaft für Pädiatrische Nephrologie. Pediatr Nephrol. 2008;23:1483–93.

    PubMed Central  PubMed  Google Scholar 

  135. Yi Z, Li Z, Wu XC, He QN, Dang XQ, He XJ. Effect of fosinopril in children with steroid-resistant idiopathic nephrotic syndrome. Pediatr Nephrol. 2006;21:967–72.

    PubMed  Google Scholar 

  136. Paik KH, Lee BH, Cho HY, Kang HG, Ha IS, Cheong HI, Jin DK, Moon KC, Choi Y. Primary focal segmental glomerular sclerosis in children: clinical course and prognosis. Pediatr Nephrol. 2007;22:389–95.

    PubMed  Google Scholar 

  137. Troyanov S. Wall CA, Miller JA, Scholey JW, Cattran DC; Toronto Glomerulonephritis Registry Group. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol. 2005;16:1061–8.

    PubMed  Google Scholar 

  138. Martinelli R, Okumura AS, Pereira LJ, Rocha H. Primary focal segmental glomerulosclerosis in children: prognostic factors. Pediatr Nephrol. 2001;16:658–61.

    CAS  PubMed  Google Scholar 

  139. Abeyagunawardena AS, Sebire NJ, Risdon RA, Dillon MJ, Rees L, Van’t Hoff W, Kumarasiri PV, Trompeter RS. Predictors of long-term outcome of children with idiopathic focal segmental glomerulosclerosis. Pediatr Nephrol. 2007;22:215–21.

    PubMed  Google Scholar 

  140. Crenshaw G, Bigler S, Salem M, Crook ED. Focal segmental glomerulosclerosis in African Americans: effects of steroids and angiotensin converting enzyme inhibitors. Am J Med Sci. 2000;319:320–5.

    CAS  PubMed  Google Scholar 

  141. Stiles KP, Abbott KC, Welch PG, Yuan CM. Effects of angiotensin-converting enzyme inhibitor and steroid therapy on proteinuria in FSGS: a retrospective study in a single clinic. Clin Nephrol. 2001;56:89–95.

    CAS  PubMed  Google Scholar 

  142. Muso E, Mune M, Yorioka N, Nishizawa Y, Hirano T, Hattori M, Sugiyama S, Watanabe T, Kimura K, Yokoyama H, Sato H, Saito T. Beneficial effect of low-density lipoprotein apheresis (LDL-A) on refractory nephrotic syndrome (NS) due to focal glomerulosclerosis (FGS). Clin Nephrol. 2007;67:341–4.

    CAS  PubMed  Google Scholar 

  143. Muso E, Mune M, Fujii Y, Imai E, Ueda N, Hatta K, Imada A, Takemura T, Miki S, Kuwahara T, Takamitsu Y, Tsubakihara Y; Kansai FGS, LDL Apheresis Treatment (K-FLAT) Study Group. Significantly rapid relief from steroid-resistant nephrotic syndrome by LDL apheresis compared with steroid monotherapy. Nephron. 2001;89:408–15.

  144. Muso E, Mune M, Fujii Y, Imai E, Ueda N, Hatta K, Imada A, Miki S, Kuwahara T, Takamitsu Y, Takemura T, Tsubakihara Y, Kansai-FGS-Apheresis Treatment (K-FLAT) Study Group. Low density lipoprotein apheresis therapy for steroid-resistant nephrotic syndrome. Kidney Int Suppl. 1999;71:122–5.

    Google Scholar 

  145. Tojo K, Sakai S, Miyahara T. Possible therapeutic application of low density lipoprotein apheresis (LDL-A) in conjunction with double filtration plasmapheresis (DFPP) in drug-resistant nephrotic syndrome due to focal glomerular sclerosis (FGS). Nihon Jinzo Gakkai Shi. 1988;30:1153–60.

    CAS  PubMed  Google Scholar 

  146. Hattori M, Chikamoto H, Akioka Y, Nakakura H, Ogino D, Matsunaga A, Fukazawa A, Miyakawa S, Khono M, Kawaguchi H, Ito K. A combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children. Am J Kidney Dis. 2003;42:1121–30.

    PubMed  Google Scholar 

  147. Yokoyama K, Sakai S, Sigematsu T, Takemoto F, Hara S, Yamada A, Kawaguchi Y, Hosoya T. LDL adsorption improves the response of focal glomerulosclerosis to corticosteroid therapy. Clin Nephrol. 1998;50:1–7.

    CAS  PubMed  Google Scholar 

  148. Okada T, Takahashi H, Ogura M, Nakao T, Shimizu T. Complete remission of steroid-resistant minimal-change nephrotic syndrome by cyclosporin after additional low-density lipoprotein apheresis treatment. Jpn J Nephrol. 1996;38:46–51 (article IN Japanese).

    CAS  Google Scholar 

  149. Franke D, Zimmering M, Wolfish N, Ehrich JH, Filler G. Treatment of FSGS with plasma exchange and immunadsorption. Pediatr Nephrol. 2000;14:965–9.

    CAS  PubMed  Google Scholar 

  150. Feld SM, Figueroa P, Savin V, Nast CC, Sharma R, Sharma M, Hirschberg R, Adler SG. Plasmapheresis in the treatment of steroid-resistant focal segmental glomerulosclerosis in native kidneys. Am J Kidney Dis. 1998;32:230–7.

    CAS  PubMed  Google Scholar 

  151. Mitwalli AH. Adding plasmapheresis to corticosteroids and alkylating agents: does it benefit patients with focal segmental glomerulosclerosis. Nephrol Dial Transplant. 1998;13:1524–8.

    CAS  PubMed  Google Scholar 

  152. Magnasco A, Ravani P, Edefonti A, Murer L, Ghio L, Belingheri M, Benetti E, Murtas C, Messina G, Massella L, Porcellini MG, Montagna M, Regazzi M, Scolari F, Ghiggeri GM. Rituximab in children with resistant idiopathic nephrotic syndrome. J Am Soc Nephrol. 2012;23:1117–24.

    PubMed Central  CAS  PubMed  Google Scholar 

  153. Loeffler K, Gowrishankar M, Yiu V. Tacrolimus therapy in pediatric patients with treatment-resistant nephrotic syndrome. Pediatr Nephrol. 2004;19:281–7.

    PubMed  Google Scholar 

  154. Bhimma R, Adhikari M, Asharam K, Connolly C. Management of steroid-resistant focal segmental glomerulosclerosis in children using tacrolimus. Am J Nephrol. 2006;26:544–51.

    CAS  PubMed  Google Scholar 

  155. Gulati S, Prasad N, Sharma RK, Kumar A, Gupta A, Baburaj VP. Tacrolimus: a new therapy for steroid-resistant nephrotic syndrome in children. Nephrol Dial Transplant. 2008;23:910–3.

    CAS  PubMed  Google Scholar 

  156. Butani L, Ramsamooj R. Experience with tacrolimus in children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2009;24:1517–23.

    PubMed Central  PubMed  Google Scholar 

  157. Roberti I, Vyas S. Long-term outcome of children with steroid-resistant nephrotic syndrome treated with tacrolimus. Pediatr Nephrol. 2010;25:1117–24.

    PubMed  Google Scholar 

  158. Pandirikkal VB, Jain M, Gulati S. Tacrolimus-induced HUS: an unusual cause of acute renal failure in nephrotic syndrome. Pediatr Nephrol. 2007;22:298–300.

  159. de Mello VR, Rodrigues MT, Mastrocinque TH, Martins SP, de Andrade OV, Guidoni EB, Scheffer DK, Martini Filho D, Toporovski J, Benini V. Mycophenolate mofetil in children with steroid/cyclophosphamide-resistant nephrotic syndrome. Pediatr Nephrol. 2010;25:453–60.

    PubMed  Google Scholar 

  160. Li Z, Duan C, He J, Wu T, Xun M, Zhang Y, Yin Y. Mycophenolate mofetil therapy for children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2010;25:883–8.

    PubMed  Google Scholar 

  161. Gargah TT, Lakhoua MR. Mycophenolate mofetil in treatment of childhood steroid-resistant nephrotic syndrome. J Nephrol. 2011;24:203–7.

    CAS  PubMed  Google Scholar 

  162. Gipson DS, Trachtman H, Kaskel FJ, Greene TH, Radeva MK, Gassman JJ, Moxey-Mims MM, Hogg RJ, Watkins SL, Fine RN, Hogan SL, Middleton JP, Vehaskari VM, Flynn PA, Powell LM, Vento SM, McMahan JL, Siegel N, D’Agati VD, Friedman AL. Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int. 2011;80:868–78.

    PubMed Central  CAS  PubMed  Google Scholar 

  163. Kyrieleis HA, Löwik MM, Pronk I, Cruysberg HR, Kremer JA, Oyen WJ, van den Heuvel BL, Wetzels JF, Levtchenko EN. Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children. Clin J Am Soc Nephrol. 2009;4:1593–600.

    PubMed Central  PubMed  Google Scholar 

  164. Requião-Moura LR, Veras de S Freitas T, Franco MF, Pereira AB, Mastroianni-Kirsztajn G. Should adolescents with glomerulopathies be treated as children or adults? Nephron Clin Pract. 2008;109:c161–7.

    PubMed  Google Scholar 

  165. Simmonds J, Grundy N, Trompeter R, Tullus K. Long-term steroid treatment and growth: a study in steroid-dependent nephrotic syndrome. Arch Dis Child. 2010;95:146–9.

    PubMed  Google Scholar 

  166. Emma F, Sesto A, Rizzoni G. Long-term linear growth of children with severe steroid-responsive nephrotic syndrome. Pediatr Nephrol. 2003;18:783–8.

    PubMed  Google Scholar 

  167. Takahashi T, Inaba S, Oshima T, Ishihara S, Toyoda Y, Kurose K, Takai R, Yoshida A, Okada T, Takada T, Yanagihara T. Growth of children with idiopathic nephrotic syndrome. The effect of steroid therapy. J Jpn Pediatr Soc. 1991;95:1850–5 (article in Japanese).

  168. Kaku Y, Ohtsuka Y, Komatsu Y, Ohta T, Nagai T, Kaito H, Kondo S, Ikezumi Y, Tanaka S, Matsumoto S, Sako M, Tsuruga K, Nakanishi K, Kamei K, Saito H, Fujinaga S, Hamasaki Y, Chikamoto H, Ishikura K, Iijima K. Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: general therapy, clinical and experimental nephrology. Clin Exp Nephrol. doi:10.1007/s10157-014-1031-9.

  169. Kranz B, Vester U, Büscher R, Wingen AM, Hoyer PF. Cyclosporine-A-induced nephrotoxicity in children with minimal-change nephrotic syndrome: long-term treatment up to 10 years. Pediatr Nephrol. 2008;23:581–6.

    PubMed Central  PubMed  Google Scholar 

  170. Drube J, Geerlings C, Taylor R, Mengel M, Ehrich JH. Fifteen-year remission of a steroid-resistant nephrotic syndrome sustained by cyclosporine A. Pediatr Nephrol. 2007;22:600–2.

    PubMed  Google Scholar 

  171. Ghiggeri GM, Catarsi P, Scolari F, Caridi G, Bertelli R, Carrea A, Sanna-Cherchi S, Emma F, Allegri L, Cancarini G, Rizzoni GF, Perfumo F. Cyclosporine in patients with steroid-resistant nephrotic syndrome: an open-label, nonrandomized, retrospective study. Clin Ther. 2004;26:1411–8.

    CAS  PubMed  Google Scholar 

  172. Chishti AS, Sorof JM, Brewer ED, Kale AS. Long-term treatment of focal segmental glomerulosclerosis in children with cyclosporine given as a single daily dose. Am J Kidney Dis. 2001;38:754–60.

    CAS  PubMed  Google Scholar 

  173. Hino S, Takemura T, Okada M, Murakami K, Yagi K, Fukushima K, Yoshioka K. Follow-up study of children with nephrotic syndrome treated with a long-term moderate dose of cyclosporine. Am J Kidney Dis. 1998;31:932–9.

    CAS  PubMed  Google Scholar 

  174. Gregory MJ, Smoyer WE, Sedman A, Kershaw DB, Valentini RP, Johnson K, Bunchman TE. Long-term cyclosporine therapy for pediatric nephrotic syndrome: a clinical and histologic analysis. J Am Soc Nephrol. 1996;7:543–9.

    CAS  PubMed  Google Scholar 

  175. Neuhaus TJ, Burger HR, Klingler M, Fanconi A, Leumann EP. Long-term low-dose cyclosporin A in steroid dependent nephrotic syndrome of childhood. Eur J Pediatr. 1992;151:775–8.

    CAS  PubMed  Google Scholar 

  176. Melocoton TL, Kamil ES, Cohen AH, Fine RN. Long-term cyclosporine A treatment of steroid-resistant and steroid-dependent nephrotic syndrome. Am J Kidney Dis. 1991;18:583–8.

    CAS  PubMed  Google Scholar 

  177. Fujinaga S, Ohtomo Y, Akashi S, Kaneko K. Chronic cyclosporine-induced nephropathy in children with nephrotic syndrome. Japanese Journal of Pediatric Nephrology. 2004;17:66–71 (article in Japanese).

    Google Scholar 

  178. Bogdanović R, Banićević M, Cvorić A. Testicular function following cyclophosphamide treatment for childhood nephrotic syndrome: long-term follow-up study. Pediatr Nephrol. 1990;4:451–4.

    PubMed  Google Scholar 

  179. Jones DP, Stapleton FB, Roy S 3rd, Wyatt RJ. Beneficial effect of second courses of cytotoxic therapy in children with minimal change nephrotic syndrome. Pediatr Nephrol. 1988;2:291–5.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The development of this guideline was solely supported by the society budget of the Japanese Society for Pediatric Nephrology. All members engaged in the guideline development submitted Conflicts of Interest declaration forms, which are retained by the Japanese Society for Pediatric Nephrology. To avoid the influence of any conflicts of interest on the contents of this guideline, discussions were made in an open manner using a mailing list system. Opinions of multiple reviewers (councilor board members of the Japanese Society for Pediatric Nephrology and an epidemiologist as an outside reviewer) and public comments were used to refine the guideline.

Kazumoto Iijima, Kenji Ishikura, and Yoshitsugu Kaku played an essential role in scientific discussion and preparation and review of the manuscript. The rest of the authors all contributed equally to the work. The authors thank for the contribution of Ms. Fujimi Kawai and Ms. Satomi Kojima, The Japan Medical Library Association, for expert consultation on the development of the guideline; Mr. Kyoshiro Yanagisawa and Ms. Yumi Yanagisawa for advice from a viewpoint of a patient and its guardian; Dr. Kaori Kikunaga, Tokyo Metropolitan Children’s Medical Center, for clerical and coordination duties; ASCA Corporation for translation and editorial supports in the preparation of the manuscript; and Dr. Noriko Kojimahara, Tokyo Women’s Medical University, Dr. Shuichi Ito, the National Center for Child Health and Development, and Dr. Shoji Kagami, the University of Tokushima, for proper and thorough review of the guideline.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kenji Ishikura.

Additional information

The Scientific Committee in the Japanese Society for Pediatric Nephrology previously published the “Clinical Practice Guideline for Pediatric Idiopathic Nephrotic Syndrome” (2013). This is the English translation from the “Medical Therapy” portion of the guideline.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ishikura, K., Matsumoto, S., Sako, M. et al. Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: medical therapy. Clin Exp Nephrol 19, 6–33 (2015). https://doi.org/10.1007/s10157-014-1030-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-014-1030-x

Keywords

Navigation